Workshop highlights include:
- Contrasting predictive value of CDX and PDX in vivo models, contextualized with time and investment available for preclinical studiesÂ
- Diving into takeaways of ADC translation: what was the most useful results gained from preclinical studies?Â
- Debating considerations for the translation of bispecific ADCs
- Laying out rationale for selecting ADC combinations and delving into preclinical characterization to best predict clinical activity